JP2023546743A - 抗ｃｄ７３抗体及びその使用 - Google Patents

抗ｃｄ７３抗体及びその使用 Download PDF

Info

Publication number
JP2023546743A
JP2023546743A JP2023548995A JP2023548995A JP2023546743A JP 2023546743 A JP2023546743 A JP 2023546743A JP 2023548995 A JP2023548995 A JP 2023548995A JP 2023548995 A JP2023548995 A JP 2023548995A JP 2023546743 A JP2023546743 A JP 2023546743A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
sequence
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546743A5 (https=
Inventor
リ，バイヨン
シア，ユ
ワン，ジョンミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akeso Pharmaceuticals Inc
Original Assignee
Akeso Biopharma Inc
Akeso Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Biopharma Inc, Akeso Pharmaceuticals Inc filed Critical Akeso Biopharma Inc
Publication of JP2023546743A publication Critical patent/JP2023546743A/ja
Publication of JP2023546743A5 publication Critical patent/JP2023546743A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023548995A 2020-10-23 2021-10-22 抗ｃｄ７３抗体及びその使用 Pending JP2023546743A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011152518 2020-10-23
CN202011152518.9 2020-10-23
PCT/CN2021/125564 WO2022083723A1 (zh) 2020-10-23 2021-10-22 抗cd73的抗体及其用途

Publications (2)

Publication Number Publication Date
JP2023546743A true JP2023546743A (ja) 2023-11-07
JP2023546743A5 JP2023546743A5 (https=) 2025-05-20

Family

ID=81291626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548995A Pending JP2023546743A (ja) 2020-10-23 2021-10-22 抗ｃｄ７３抗体及びその使用

Country Status (11)

Country Link
US (1) US20240018254A1 (https=)
EP (1) EP4234579A4 (https=)
JP (1) JP2023546743A (https=)
KR (1) KR20230125774A (https=)
CN (2) CN120590533A (https=)
AU (1) AU2021363350A1 (https=)
CA (1) CA3196299A1 (https=)
IL (1) IL302182A (https=)
MX (1) MX2023004713A (https=)
WO (1) WO2022083723A1 (https=)
ZA (1) ZA202304591B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022002028A2 (pt) * 2019-08-02 2022-04-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anticorpo anti-pd-1 e uso farmacêutico do mesmo
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
JP2017534648A (ja) * 2014-11-11 2017-11-24 メディミューン リミテッド 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
JP2017537620A (ja) * 2014-11-21 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
JP2018501197A (ja) * 2014-11-10 2018-01-18 メディミューン リミテッド Ｃｄ７３特異的結合分子及びその使用
JP2018502151A (ja) * 2015-01-15 2018-01-25 欧詩漫生物股▲ふん▼有限公司Ｏｓｍ Ｂｉｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． 真珠タンパクの調製方法、該方法で調製される水溶性真珠タンパク及び酸可溶性真珠タンパク
WO2018110555A1 (ja) * 2016-12-13 2018-06-21 アステラス製薬株式会社 抗ヒトｃｄ７３抗体
WO2018215535A1 (en) * 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
JP2019503709A (ja) * 2015-12-09 2019-02-14 コーバス・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｄ７３抗体
JP2019514844A (ja) * 2016-03-04 2019-06-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｃｄ７３抗体を用いた併用療法
JP2020515508A (ja) * 2017-01-24 2020-05-28 アイ−エムエービー バイオファーマ ユーエス リミテッド 抗ｃｄ７３抗体およびその使用
JP2020530263A (ja) * 2017-06-22 2020-10-22 ノバルティス アーゲー Ｃｄ７３に対する抗体分子及びその使用
JP2020186244A (ja) * 2014-10-10 2020-11-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｃｄ７３遮断
JP2021516057A (ja) * 2018-03-09 2021-07-01 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ７３抗体及びその使用
JP2023522365A (ja) * 2020-04-22 2023-05-30 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３抗体とその利用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2016131950A1 (en) * 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN111434688A (zh) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
CA3176321A1 (en) * 2020-04-22 2021-10-28 Peng Zhang Anti-cd73-anti-pd-1 bispecific antibody and use thereof

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020186244A (ja) * 2014-10-10 2020-11-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｃｄ７３遮断
JP2018501197A (ja) * 2014-11-10 2018-01-18 メディミューン リミテッド Ｃｄ７３特異的結合分子及びその使用
JP2017534648A (ja) * 2014-11-11 2017-11-24 メディミューン リミテッド 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
JP2017537620A (ja) * 2014-11-21 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
JP2018502151A (ja) * 2015-01-15 2018-01-25 欧詩漫生物股▲ふん▼有限公司Ｏｓｍ Ｂｉｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． 真珠タンパクの調製方法、該方法で調製される水溶性真珠タンパク及び酸可溶性真珠タンパク
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
JP2019503709A (ja) * 2015-12-09 2019-02-14 コーバス・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｄ７３抗体
JP2019514844A (ja) * 2016-03-04 2019-06-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｃｄ７３抗体を用いた併用療法
WO2018110555A1 (ja) * 2016-12-13 2018-06-21 アステラス製薬株式会社 抗ヒトｃｄ７３抗体
JP2020515508A (ja) * 2017-01-24 2020-05-28 アイ−エムエービー バイオファーマ ユーエス リミテッド 抗ｃｄ７３抗体およびその使用
WO2018215535A1 (en) * 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
JP2020530263A (ja) * 2017-06-22 2020-10-22 ノバルティス アーゲー Ｃｄ７３に対する抗体分子及びその使用
JP2021516057A (ja) * 2018-03-09 2021-07-01 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ７３抗体及びその使用
JP2023522365A (ja) * 2020-04-22 2023-05-30 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３抗体とその利用

Also Published As

Publication number Publication date
EP4234579A1 (en) 2023-08-30
CN114478768B (zh) 2025-05-30
EP4234579A4 (en) 2025-03-12
US20240018254A1 (en) 2024-01-18
ZA202304591B (en) 2025-08-27
KR20230125774A (ko) 2023-08-29
WO2022083723A1 (zh) 2022-04-28
IL302182A (en) 2023-06-01
CA3196299A1 (en) 2022-04-28
CN120590533A (zh) 2025-09-05
AU2021363350A1 (en) 2023-06-22
MX2023004713A (es) 2023-05-09
CN114478768A (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
US20250041409A1 (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
KR102503084B1 (ko) 항-ctla4 및 항-pd-1 이작용성 항체, 이의 약제학적 조성물 및 이의 용도
CN113527489B (zh) 抗cd73的抗体及其用途
CN114478768B (zh) 抗cd73的抗体及其用途
US20240352153A1 (en) Pharmaceutical composition and use
EP4253414A1 (en) Anti-tigit antibody, and pharmaceutical composition and use thereof
CN114106182B (zh) 抗tigit的抗体及其用途
WO2024051223A1 (zh) 药物组合及用途
WO2023246247A1 (zh) 药物组合物及其用途
HK40093416A (en) Anti-cd73 antibody and use thereof
EA051023B1 (ru) Фармацевтическая композиция и набор, содержащие антитело против cd73, и их применение в способе лечения опухоли
CA3034849C (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
JP2026511828A (ja) 二重特異性抗体、医薬組成物及び用途
HK40121274A (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
HK40093009A (en) Anti-tigit antibody, and pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421